Bank of America Reaffirms Buy Rating for Insmed (NASDAQ:INSM

Bank of America reaffirmed their buy rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Bank of America currently has a $40.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on INSM. Barclays raised their […]

Related Keywords

United States , America , Sara Bonstein , Capital International Investors , Wolfe Research , Securities Exchange Commission , Insmed Incorporated , Norges Bank , Barclays , Loomis Sayles Co , Insmed Company Profile , Wells Fargo Company , Vanguard Group Inc , Free Report , Moderate Buy , Get Free Report , Exchange Commission , John Drayton Wise , International Investors , Insmed Daily ,